380 related articles for article (PubMed ID: 25190250)
1. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
2. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
4. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
6. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegård M; Forsberg K; Gruber A; Haglöf Kviele H; Johansson P; Lauri B; Mellqvist UH; Swedin A; Svensson M; Näsman P; Alici E; Gahrton G; Aschan J; Nahi H
Br J Haematol; 2014 Mar; 164(5):684-93. PubMed ID: 24313224
[TBL] [Abstract][Full Text] [Related]
7. The role of novel drugs in multiple myeloma.
Dimopoulos MA; Kastritis E
Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
[No Abstract] [Full Text] [Related]
8. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
9. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and lenalidomide effective in myeloma.
Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
[No Abstract] [Full Text] [Related]
11. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Nagano S; Mori M; Kato A; Ono Y; Aoki K; Arima H; Takiuchi Y; Tabata S; Yanagita S; Matsushita A; Ishikawa T; Imai H; Takahashi T
Intern Med; 2013; 52(10):1101-5. PubMed ID: 23676598
[TBL] [Abstract][Full Text] [Related]
13. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
14. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
[TBL] [Abstract][Full Text] [Related]
15. Novel agents for multiple myeloma treatment.
Ribatti D; Vacca A
Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
[No Abstract] [Full Text] [Related]
16. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
17. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
[TBL] [Abstract][Full Text] [Related]
18. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to the management of myeloma.
Rajkumar SV
Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
[TBL] [Abstract][Full Text] [Related]
20. [The plasma cell myeloma--molecular pathogenesis and target therapies].
Hess U
Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
